Bo Lang
About Bo Lang
Bo Lang is a Senior Principal Scientist in Drug Product Development at Bristol Myers Squibb, with extensive experience in formulation development, biopharmaceutics, and Risk Evaluation and Mitigation Strategies (REMS).
Company
Bo Lang currently works at Bristol Myers Squibb in New Brunswick, New Jersey, United States. Bristol Myers Squibb is a well-established pharmaceutical company known for its focus on innovative medicines and therapies.
Title
Bo Lang holds the position of Senior Principal Scientist in Drug Product Development at Bristol Myers Squibb. This role involves leading various formulation and biopharmaceutics assessments, particularly for poorly permeable clinical stage compounds.
Education and Expertise
Bo Lang has a strong academic background in biopharmaceutical sciences. He earned a Ph.D. in Pharmaceutics from The University of Texas at Austin, and previously studied in the Ph.D. program in Cellular and Molecular Biology at the University of Alabama at Birmingham. He also holds a Bachelor’s degree in Bioscience from the University of Science and Technology of China. His expertise includes drug product development, formulation platforms, biopharmaceutics, and REMS programs.
Career Background
Bo Lang has an extensive career in the pharmaceutical industry. Before his current role, he served as Principal Scientist and held various investigator positions at Bristol Myers Squibb between 2015 and 2022. He also gained experience as a Formulation Scientist at Mylan and interned at Gilead Sciences. Earlier in his career, he worked as a Graduate Research Assistant and Teaching Assistant at The University of Texas at Austin, and as an Undergraduate Research Assistant at the University of Science and Technology of China.
Achievements
Bo Lang has contributed significantly to drug product development and patient safety. He co-leads a research collaboration with University College Dublin focused on the oral delivery of poorly permeable compounds. He has experience developing Risk Evaluation and Mitigation Strategies (REMS) for medications such as REVLIMID, POMALYST, and THALOMID. His work has helped ensure medications are used safely and effectively, addressing unmet medical needs and managing serious risks associated with drug use.